Previous 10 | Next 10 |
Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results - Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT - PR Newswire TEL AVIV, Israel , May 13, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nas...
The WHO approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the global pandemic. CoronaVac is the first China-developed COVID-19 vaccine under consideration in Europe, joining vaccines from CureVac, Novavax and a Russian ...
Galmed Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Business Update on Thursday May 13 PR Newswire TEL AVIV, Israel , May 6, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stag...
Galmed Pharmaceuticals (GLMD) announces that China's National Medical Products Administration ((NMPA)) has granted approval for the Investigational New Drug ((IND)) application for the company's Phase 3 study of Aramchol for the treatment of non-alcoholic Steatohepatitis ((NASH)) & f...
Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global ...
Galmed Pharmaceuticals Ltd. (GLMD) Q4 2020 Earnings Conference Call March 18, 2021 08:30 AM ET Company Participants Allen Baharaff - President & Chief Executive Officer Yohai Stenzler - Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Steve Seedhouse - Raymon...
Galmed (GLMD): FY GAAP EPS of -$1.35 misses by $0.11.Cash and cash equivalents, restricted cash, short-term deposits and marketable debt securities totaled $51.0 million as of December 31, 2020, compared with $75.6 million as of December 31, 2019.Press Release For further details see: G...
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results - Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT - PR Newswire TEL AVIV, Israel , March 18, 2021 /PRNewswire/ -- Galmed Pharmaceut...
Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER Amilo-5MER is believed to have significant effect in the treatment of chronic inflammation PR Newswire TEL AVIV, Israel , March 16, 2021 /PRNewswire/ -- Gal...
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update on Thursday March 18 PR Newswire TEL AVIV, Israel , March 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company...
News, Short Squeeze, Breakout and More Instantly...
Galmed Pharmaceuticals Ltd. Company Name:
GLMD Stock Symbol:
NASDAQ Market:
Galmed Pharmaceuticals Ltd. Website: